ANI Pharmaceuticals, Inc. (ANIP)
| Previous close | 56.73 |
| Open | 56.22 |
| Bid | 55.55 x 100 |
| Ask | 55.94 x 100 |
| Day's range | 55.67 - 56.22 |
| 52-week range | 48.20 - 70.81 |
| Volume | |
| Avg. volume | 354,671 |
| Market cap | 1.172B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 46.82 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%
PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®. "We are proud to announce the FDA approval and commercialization of Ketoconazole Shampoo, 2%, an
- GlobeNewswire
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expe
- GlobeNewswire
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceutical
